The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy

Journal of the Neurological Sciences

Volumn 271, Issue 1-2, 2008, Pages 87-90

  Heo, Jae Hyeok ^a   Lee, Soon Tae ^b   Chu, Kon ^b   Kim, Manho ^b  

^a Seoul Medical Center   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Buspirone; Estrogen; Olivopontocerebellar atrophy

Indexed keywords

BUSPIRONE; CONJUGATED ESTROGEN; ESTROGEN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DYSARTHRIA; FEMALE; GAZE; HUMAN; MALE; NEUROPROTECTION; NYSTAGMUS; OLIVOPONTOCEREBELLAR ATROPHY; PRIORITY JOURNAL;

ADULT; BUSPIRONE; DRUG THERAPY, COMBINATION; ESTROGENS; EVALUATION STUDIES AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OLIVOPONTOCEREBELLAR ATROPHIES; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX;

EID: 45849109168     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.03.016     Document Type: Article

References (36)

1. Berciano J., Boesch S., Perez-Ramos J.M., et al. Olivopontocerebellar atrophy: toward a better nosological definition. Mov Disord 21 10 (Oct 2006) 1607-1613
2. Jacobs B.L., and Fornal C.A. 5-HT and motor control: a hypothesis. Trends Neurosci 16 (1993) 46-52
3. Friedman J.H. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord 12 (1997) 613-614
4. Wolozin B., Kellman W., Ruosseau P., et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
5. Jick H., Zornberg G.L., Jick S.S., et al. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
6. Henderson A.S., Jorm A.F., Christensen H., et al. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 12 (1997) 926-930
7. Cornelius C., Fastbom J., Winblad B., et al. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 23 3 (May-Jun 2004) 135-143
8. Mulnard R.A., Cotman C.W., Kawas C., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trialAlzheimer's Disease Cooperative Study. JAMA 283 (2000) 1007-1015
9. Currie L.J., Harrison M.B., Trugman J.M., et al. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 61 (2004) 886-888
10. Dluzen D.E., McDermott J.L., and Liu B. Estrogen as a neuroprotectant against MPTP-induced neurooxicity in C57/B1 mice. Neurotoxicol Teratol 18 (1996) 603-606
11. D'Astous M., Morissete M., and Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 47 (2004) 1180-1188
12. Gardiner S.A., Morrison M.F., Mozley P.D., et al. Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatr 12 (2004) 621-630
13. Fillit H., Weinreb H., Cholst I., et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 11 (1986) 337-345
14. Honjo H., Ogino Y., Naitoh K., et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 34 (1989) 521-525
15. Ohkura T., Isse K., Akazawa K., et al. Evaluation of estrogen in female patients with dementia of the Alzheimer type. Endocr J 41 (1994) 361-371
16. Asthana S., Craft S., Baker L.D., et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 24 6 (Aug 1999) 657-677
17. Du B., Ohmichi M., Takahashi K., et al. Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade. J Endocrinol 183 (2004) 605-615
18. Biewenga E., Cabell L., and Audesirk T. Estrogen and raloxifene protect cultured SN4741 neurons against oxidative stress. Neurosci Lett 373 (2005) 179-183
19. Singer C.A., Figueroa-Masot X.A., Batchelor R.H., et al. The mitogen-activated protein kinase pathway mediates estrogen enuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 19 (1999) 2455-2463
20. Sierra A., Azcoitia I., and Garcia-Sequra L. Endogenous estrogen formation is neuroprotective in model of cerebellar ataxia. Endocrine 21 1 (Jun 2003) 43-51
21. Tsutsui K., Sakamoto H., Shikimi H., et al. Organizing actions of neurosteroids in the Purkinje neuron. Neurosci Res 49 (2004) 273-279
22. Baetens D., Garcia-Sequra L.M., and Perrelet A. Effects of climbing fiber destruction on large dendrite spines of Purkinje cells. Exp Brain Res 48 2 (1982) 256-262
23. Pozzi S., Benedusi V., Maggi A., et al. Estrogen action in neuroprotection and brain inflammation. Ann N Y Acad Sci 1089 (Nov 2006) 302-323
24. Meda C., Vegeto E., Pollio G., et al. Oestrogen prevention of neural cell death correlates with decreased expression of mRNA for the pro-apoptotic protein nip-2. J Neuroendocrinol 12 11 (Nov 2000) 1051-1059
25. Behl C., Skutella T., Lezoualc'h F., et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51 4 (Apr 1997) 535-541
26. Bebo Jr. B.F., Fyfe-Johnson A., Adlard K., et al. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 166 3 (Feb 1 2001) 2080-2089
27. Takei A., Hamada T., Yabe I., et al. Treatment of cerebellar ataxia with 5-HT1A agonist. The cerebellum 4 (2005) 211-215
28. Saito Y., Miwa S., Yamana T., et al. Clinical therapeutical trial of oral tandospirone for cerebellar ataxia. Nagoya Shiritu Byouin Kiyou 21 (1998) 5-8
29. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg psychiatry 52 (1989) 78-89 (special supplement)
30. Trouillas P., Takayanagi T., Hallett M., et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145 2 (1997) 205-211
31. Zhao L., and Brinton R.D. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin®) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neuroscience 7 (2006) 24
32. Giri S., Thompson P.D., Taxel P., et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 137 (1998) 359-366
33. Randell K.M., Honkanen R.J., Komulainen M.H., et al. Hormone replacement therapy and risk of falling in early postmenopausal women - a population-based study. Clin Endocrinol 54 (2001) 769-774
34. Naessen T., Lindmark B., and Larsen H.C. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol 177 2 (Aug 1997) 412-416
35. Bates B., Rios M., Trumpp A., et al. Neurotrophin-3 is required for proper cerebellar development. Nat Neurosci 2 (1999) 115-117
36. Schwartz P.M., Borghesani P.R., Levy R.L., et al. Abnormal cerebellar development and foliation in BDNF-/-mice reveals a neurotrophins in CNS patterning. Neuron 19 2 (Aug 1997) 269-281